Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vitamin A tracer Clear all
Completed Phase 1 Interventional Results available

Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

NCT02937350
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
D6-25-hydroxyvitamin D3
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 4, 2026, 6:43 PM EDT
Terminated Phase 3 Interventional

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

NCT00273338
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, docetaxel
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
159
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Not applicable Interventional

Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation

NCT04342728
View directory record Official record
Conditions
COVID, Corona Virus Infection
Interventions
Ascorbic Acid, Zinc Gluconate, Ascorbic Acid and Zinc Gluconate, Standard of Care
Dietary Supplement · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

NCT02410772
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine, rifapentine and moxifloxacin, control
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
San Francisco, California • New York, New York • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Results available

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

NCT00257920
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
Interventions
Zemplar® injection, Hectorol® injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Bellevue, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 3 Interventional

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

NCT01836575
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Pemetrexed, Carboplatin
Drug
Lead sponsor
Instituto Nacional de Cancer, Brazil
Government
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies

NCT00055263
View directory record Official record
Conditions
Neoplasms
Interventions
DN-101
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Buffalo, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 4, 2026, 6:43 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab, Placebo
Biological · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 25 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 4, 2026, 6:43 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Renal Metabolism of Glycolate to Oxalate

NCT04437225
View directory record Official record
Conditions
Healthy
Interventions
Low oxalate controlled Diet, Primed, continuous intravenous infusion of 13C2-Glycolate, Bolus intravenous infusion of 13C2-Glycolate, Oral bolus administration of 13C2-Glycolate
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 4 Interventional

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

NCT00073710
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

NCT03118570
View directory record Official record
Conditions
Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
Interventions
setrusumab, Calcium, Vitamin D, zoledronic acid (optional)
Drug · Dietary Supplement
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Jacksonville, Florida • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Not applicable Interventional Results available

Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

NCT01222273
View directory record Official record
Conditions
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions
cholecalciferol (Vitamin D3)
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 4, 2026, 6:43 PM EDT
Recruiting Phase 1 Interventional

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

NCT07665723
View directory record Official record
Conditions
Active Ulcerative Colitis
Interventions
Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

NCT00742716
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTA018 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 4, 2026, 6:43 PM EDT
Not listed Not applicable Interventional

Vitamin D in Pediatric Asthma: a Randomized Controlled Open-label Pilot Trial

NCT02054975
View directory record Official record
Conditions
Asthma, Vitamin D Deficiency
Interventions
Vitamin D2 + vitamin D3, Vitamin D3
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Not applicable Interventional

Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis

NCT04966897
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
GlycosBio Nutritional Supplement + PERT placebo, Standard Nutritional Supplement + PERT
Dietary Supplement
Lead sponsor
GlycosBio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin B6 Dependence of One-Carbon Metabolism

NCT00877812
View directory record Official record
Conditions
Vitamin B6 Deficiency
Interventions
Arm 1 glycine and leucine, Arm 2 Intervention of Serine and methionine infusion
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
20 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

Open Label Study: Treatment of ALS Fatigue With PolyMVA

NCT04557410
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PolyMVA
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 4, 2026, 6:43 PM EDT
Withdrawn Phase 2 Interventional

Medications After Adolescent Bariatric Surgery

NCT04572217
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Topiramate, Phentermine
Drug
Lead sponsor
Janey Pratt
Other
Eligibility
12 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

NCT03363815
View directory record Official record
Conditions
Heathy Volunteer
Interventions
CC-90001, Omeprazole, Midazolam, Warfarin, Vitamin K, Rosuvastatin, Metformin, Digoxin, Nintedanib
Drug · Dietary Supplement
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Early Phase 1 Interventional

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

NCT05891119
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab
Dietary Supplement · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Results available

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

NCT00823303
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Paricalcitol, Calcitriol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 4, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

NCT05932732
View directory record Official record
Conditions
Cutis Laxa Facialis, Xeroderma
Interventions
HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System
Device · Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 4, 2026, 6:43 PM EDT